This study also reveals that MUC16 mutation and lower CYT score are associated with decreased RFS in patients who were node‐positive ESCC patients, providing important clues for personalized treatment and monitoring, and offering new ideas for improving the prognosis of these patients. Here, MUC16 is linked to esophageal squamous cell carcinoma.